Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could be ...

You can't spell Ainsworth without AI. It's a small linguistic coincidence, but it's also a neat shorthand for the conversation I had with John Ainsworth, Executive Vice President and General Manager, ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific antibodies. ABL Bio will receive an upfront payment and potential milestone ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple therapeutics using the Grabody-B platform. Under the terms announced Nov. 12, ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic. ABL, a Korean biotech that is partnered with companies ...

Progress Software Corporation (NASDAQ:PRGS) is one of the most undervalued technology stocks to buy according to analysts. On September 29, Progress Software announced the early customer review and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

ALEXANDRIA, Va.--(BUSINESS WIRE)--Oxford Finance LLC (“Oxford” or the “Company”), a leading specialty finance firm, is pleased to announce the appointment of Nick McDearis to lead Asset-Based Lending ...

ABL Bio announced on the 9th that it has terminated the technology introduction contract signed with the domestic corporations IntoCell. The company explained the reason for the contract termination ...